EU reportedly in talks with J&J to secure doses of its COVID-19 vaccine

pharmafile | June 19, 2020 | News story | Medical Communications, Research and Development, Sales and Marketing COVID-19, EU, Europe, J&J, JJ, Vaccine 

It has been reported that the European Union is currently negotiating a deal with pharma giant Johnson & Johnson to reserve or buy upfront the COVID-19 vaccine the latter currently has in development.

The reports originated from the testimonies of two European Union health officials, Reuters reported. But due to the confidential nature of the discussions, forthcoming details on the potential deal were scarce.

The European Commission declined to comment on the story. Johnson & Johnson has been transparent about its efforts working with national governments and international organisation in its development of a vaccine candidate to combat COVID-19, but would not elaborate on speculation around a deal with the EU.

The pharma firm is set to push its candidate into human trials in July. It is anticipated that the deal between the company and the EU could be revealed as early as next week, but it is currently closely under wraps and there’s still a chance it could fall through.

If the story transpires to be true, the deal would mark the first partnership signed under the €2 billion emergency fund mandated by the EU across all 27 member states. The fund is designed to fund and secure the procurement of COVID-19 vaccine candidates from up to six different developers.

Matt Fellows

Related Content


Vaxart shares topline data from phase 2 study of norovirus vaccine candidate

Vaxart has announced topline data from its phase 2 challenge study which assessed its oral …

Valneva and Pfizer share positive results from phase 2 trial for Lyme disease vaccine candidate

Valneva and Pfizer have announced positive paediatric and adolescent immunogenicity and safety data for their …

ACM Biolabs shares positive results from phase 1 SARS-CoV-2 booster vaccine trial

ACM Biolabs has announced positive topline results from its phase 1 trial of ACM-001, an …

Latest content